Vaxart, Inc. Files 8-K with Regulatory Updates

TL;DR

Vaxart filed an 8-K on Aug 27th covering Reg FD, other events, and financials.

AI Summary

Vaxart, Inc. filed an 8-K on August 29, 2025, reporting events as of August 27, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, previously known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is incorporated in Delaware and headquartered in South San Francisco, CA.

Why It Matters

This 8-K filing provides important updates and disclosures from Vaxart, Inc. to the SEC, which can affect investor understanding of the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting standard corporate events and disclosures, not indicating any immediate material adverse changes.

Key Players & Entities

• Vaxart, Inc. (company) — Registrant
• August 27, 2025 (date) — Earliest event reported date
• August 29, 2025 (date) — Filing date
• Aviragen Therapeutics, Inc. (company) — Former company name
• Biota Pharmaceuticals, Inc. (company) — Former company name
• NABI BIOPHARMACEUTICALS (company) — Former company name
• Delaware (jurisdiction) — State of incorporation
• South San Francisco, CA (location) — Business address city and state

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
• $1.00 — Company's common stock had fallen below $1.00 per share for 30 consecutive business d

Filing Documents

• vxrt20250829_8k.htm (8-K) — 34KB
• ex_858217.htm (EX-99.1) — 12KB
• 0001437749-25-028047.txt ( ) — 180KB
• vxrt-20250827.xsd (EX-101.SCH) — 3KB
• vxrt-20250827_def.xml (EX-101.DEF) — 11KB
• vxrt-20250827_lab.xml (EX-101.LAB) — 15KB
• vxrt-20250827_pre.xml (EX-101.PRE) — 11KB
• vxrt20250829_8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure. On August 13, 2025, Vaxart, Inc. (the "Company") issued a press release announcing the Decision discussed below under Item 8.01. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be deemed incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof regardless of any general incorporation language in such filing.

01

Item 8.01 Other Events. As previously reported, on July 2, 2024, the Company received a written notice from the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that because the closing bid price for the Company's common stock had fallen below $1.00 per share for 30 consecutive business days, it no longer complied with the minimum bid price requirement (the "Minimum Bid Price Requirement") for continued listing under Nasdaq Listing Rule 5550(a)(2) on The Nasdaq Capital Market. The Company was provided until December 30, 2024, to regain compliance with the Minimum Bid Price Requirement, which was subsequently extended to June 30, 2025. On July 1, 2025, the Company received a written notification from the Staff of its determination to delist the Company's common stock as a result of the Company's ongoing failure to comply with the Minimum Bid Price Requirement, unless the Company were to timely request an appeal of its determination before the Nasdaq Hearings Panel (the "Panel") by July 8, 2025. The Company timely requested a hearing before the Panel to appeal the delisting determination by the Staff. The Panel considered the Company's appeal at a hearing held on August 14, 2025. On August 27, 2025, the Panel issued a written decision (the "Decision") to the Company and determined to grant the Company's request to continue its listing on Nasdaq, subject to the following conditions: 1. On or before September 5, 2025, the Company shall obtain shareholder approval for a reverse stock split ("RSS"); 2. On or before October 6, 2025, the Company shall complete a RSS; and 3. On or before October 17, 2025, the Company shall demonstrate compliance with the Minimum Bid Price Requirement. The Decision noted that, if the Company fails to obtain approval of the RSS at the September 5, 2025 special meeting of stockholders, the Panel will delist the Company's securities. It is a requirement during the excepti

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated August 29, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 29, 2025 VAXART, INC. By: /s/ Steven Lo Steven Lo President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR